Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bladder Cancer Market Wide Open As Tecentriq Fails Confirmatory 2L Trial

10 May 2017

• By Sukaina Virji

SC1705_Sharks_194344223_1200 — Shark-infested waters: Roche failure highlights competitive risks • Source: Shutterstock

Related Content

AstraZeneca's Imfinzi Debuts In Bladder Cancer With Combo Coming Soon

01 May 2017

Pressure On Tecentriq: Bladder Cancer Heats Up With Opdivo Approval, Keytruda Filing

03 Feb 2017

Related Companies

Roche Holding AG

Merck & Co., Inc.

Merck KGaA

Pfizer Inc.

AstraZeneca PLC

Bristol Myers Squibb Company

Additional Topics

Commercial Clinical Trials Cancer BioPharmaceutical

More from Business

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.